are noninferior to newer generation DES with durable polymers (Xience, Resolute) with regards to composite clinical endpoints. Recent evidence suggests superiority of Orsiro vs. Xience with regards to target lesion failure at 12 months.

Patients treated with Orsiro stents were shown to have a lower rate of definite stent thrombosis than those treated with Nobori stents. This difference may be related to the thickness of the metallic stent scaffold. An observed benefit in the subgroup of patients with STEMI in patients treated with Orsiro vs. Xience warrants confirmation in dedicated trials.